

28-16-02

6P 1653

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): **IHLENFELDT et al.**

Docket No.

**BMID9918CUS**

Serial No.

**10/025,826**

Filing Date

**December 19, 2001**


Examiner

**To Be Assigned**

Group Art Unit

**1653**

Invention: **STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS**



I hereby certify that this **Invention Disclosure Statement**

*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 15, 2002

*(Date)*

MICHELE Wilson

*(Typed or Printed Name of Person Mailing Correspondence)*

Michelle Wilson

*(Signature of Person Mailing Correspondence)*

**EL841986580US**

*("Express Mail" Mailing Label Number)*

**Note: Each paper must have its own certificate of mailing.**

**RECEIVED**

**AUG 20 2002**

**TECH CENTER 1600/2900**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**BMID9918CUS**

In Re Application Of: **IHLENFELDT et al.**


Serial No.  
**10/025,826**

Filing Date  
**December 19, 2001**

Examiner  
**To Be Assigned**

Group Art Unit  
**1653**

Title: **STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS**



Address to:  
**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**RECEIVED**

**AUG 20 2002**

**TECH CENTER 1600/2900**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
BMID9918CUS

In Re Application: **IHLENFELDT et al.**


Serial No.  
10/025,826

Filing Date  
December 19, 2001

Examiner  
To Be Assigned

Group Art Unit  
1653

**STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS**



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **50-0877** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

Signature

Dated: **8/14/02**

Kenneth J. Waite, Reg. No. 45,189  
Roche Diagnostics Corporaiton  
9115 Hague Road, Bldg. D  
P.O. Box 50457  
Indianapolis, IN 46250-0457  
Telephone: (317) 521-3104  
Facsimile: (317) 521-2883

**RECEIVED**

**AUG 20 2002**

**TECH CENTER 1600/2900**

cc:





# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

BMID9918CUS

Application Number

10/025,826

Applicant(s)

IHLENFELDT, et al.

Filing Date

December 21, 2001

Group Art Unit

1653

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

13

Perkin Elmer Cetus (catalog, 1988) "GeneAmp DNA Amplification Reagent Kit"

14

Promega catalog (1992-1993, page 170 and web site)

15

Promega website (<http://egi.promega.com/catalog/catinfo.asp?idx=1018>)

16

Sambrook et al., "Molecular Cloning: A Laboratory Manual." 1992, 10.6-10.17 and 13.3-13.6



RECEIVED

AUG 20 2002

EXAMINER

DATE CONSIDERED

TECH CENTER 1600/2900

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.